Pliant claims early win for integrin inhibitor in challenging IPF space — shares soar
With a number of companies — including Bristol Myers Squibb — looking to drug TGF-β for a spectrum of cancers and fibrotic diseases, Pliant Therapeutics is touting early data for its TGF-β inhibitor for idiopathic pulmonary fibrosis (IPF).
Pliant’s Phase II trial for its lead candidate met the primary endpoint in tolerability, as 65 of 67 patients completed the 12-week treatment course, the Bay Area biotech announced yesterday.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.